Europe’s Biotech Grants: A Lifeline or a Leash?
Europe’s biotech sector has always been fond of government grants. Programs like Horizon Europe, with its eye-watering €95.5
To Quad or Not to Squad?
Have you noticed something peculiar creeping into the corporate world? A proliferation of titles that sound less like professional roles
Serial Founders: The Myth, the Bias, and the LinkedIn Title
Ah, the serial founder. That darling of venture capital, the endlessly inventive entrepreneur who builds company after company, racking up
The problem with WACC
The Weighted Average Cost of Capital (WACC) is a foundational metric in corporate finance, designed to evaluate the opportunity cost
The problem with CAPM
The Capital Asset Pricing Model (CAPM) is one of the most widely used and taught frameworks in finance, offering a
Boardroom Dreams: Why Everyone Wants to Be a Board Member (But Few Should Be)
It seems everyone these days is angling for a board seat. With the rise of startups and small businesses, LinkedIn
From Hobbyists to Hustlers: The Investor Boom That Rarely Scales
It seems everyone wants to be an investor these days. Armed with a LinkedIn bio touting "angel investor"
Europe’s New Health Technology Assessment Framework: Progress or Pitfall?
On January 12, 2025, the European Union’s Health Technology Assessment Regulation (HTAR) came into force, introducing a centralized framework
The CAIA in Biotech and Pharma: A Linear Compass for a Tangled Jungle
The Chartered Alternative Investment Analyst (CAIA) designation positions itself as the key to unlocking the mysteries of hedge funds, private
The CFA in Biotech and Pharma: Predicting the Unpredictable with the Wrong Tools
The Chartered Financial Analyst (CFA) designation once sat atop the financial world like a gold standard minted for modern markets.
